HARMONY · The Physics Layer of Biology

Physics-first
drug discovery.

HARMONY is an AI platform built on a new branch of protein physics — one that sees what no other platform can. We are finding drug candidates for cancer, diabetes, and cardiac disease at a speed and accuracy that has never been achieved before.

We are moving fast. We'd like you to move with us.

See How It Works Investor Inquiries

The tools being used today are blind to what matters most.
We built the tool that sees.

Every major AI drug discovery platform trains on drugs that already exist. HARMONY calculates from first principles — the same way an engineer designs a bridge before pouring concrete, not after it fails.

The Problem HARMONY Solves

$2.6 billion. Average cost to bring one drug to market.

90% of candidates fail in clinical trials. HARMONY was built to change that number.

$157B

Target market today — Oncology and Rare Disease, growing to $350B+ with Agriculture and Industrial

87.4%

Accuracy predicting real clinical drug outcomes across 243 blinded patient cases

93%

Blind prospective accuracy across 149 cancer cases — EGFR, MET, ALK, and RET

36/36

Blind predictions correct across 5 independent peer-reviewed datasets — 100% record

Where HARMONY Is Working

Three of medicine's hardest problems. One platform.

HARMONY does not specialize in one disease. It reads protein physics — and protein physics governs every disease. Here is where we are right now.

Oncology

Cancer

HARMONY identified a single molecular scaffold active across four consecutive nodes of the MAPK cancer pathway — a combination no approved drug currently achieves. This is the kind of breadth pharma partners pay billions to license.

Metabolic

Diabetes

In congenital hyperinsulinism — a rare, life-threatening condition that strikes infants — HARMONY designed a novel drug candidate from protein physics alone. That candidate is now advancing to wet lab validation at Scientist.com.

Cardiac

Heart Disease

HARMONY detects the resistance mechanisms that make cardiac drugs fail — before a molecule is ever synthesized. The cost of missing this in traditional development: $200M and four years, per compound, per miss.

The Platform

AI powered by physics, not pattern matching.

Most AI drug discovery platforms are sophisticated search engines — they find molecules that look like drugs that already worked. HARMONY is different in kind, not degree. It computes from the laws of physics. That is why it finds molecules that have never existed before.

A Discovery No One Else Has Made

Speed That Changes the Economics

Built-In Safety

A Platform, Not a Pipeline

Latest · Moving Fast

New results, roughly every two weeks.

Validation · 2026

HARMONY achieves 36/36 blind predictions correct across 5 independent peer-reviewed datasets. Every call time-stamped before the literature was checked.

2026

Pipeline · Jul 2026

Single scaffold shows confirmed activity across four consecutive MAPK cancer pathway targets — a combination no approved drug currently covers.

July 2026

IP · Jul 2026

7 USPTO provisional patents confirmed. Priority chain dating to August 2025. PARP1, RET, BCR-ABL1, and ABCA4 filings complete.